BRAIN MATRIX Platform Study

Head AI 400x400
BRAIN MATRIX is a first-of-its-kind clinical trial

The clinical trial protocol for the Tessa Jowell BRAIN MATRIX Platform Study has been published in the journal BMJ Open

The study, named in honour of the late Baroness Tessa Jowell who bravely shared her diagnosis of a brain tumour on her 70th birthday, is run through Cancer Research UK Clinical Trials Unit and led by Professor Colin Watts, Chair of the Birmingham Brain Cancer Program and Honorary Consultant Neurosurgeon at University Hospitals Birmingham.

BRAIN MATRIX is a first-of-its-kind clinical trial platform that will enable researchers to collect a rich genomic, pathological and imaging dataset to provide patients and clinicians with a fully integrated diagnosis of their disease. The end goal of this platform is to accelerate the development and delivery of brain tumour clinical trials and provide greater access to novel targeted treatments and improved outcomes for patients, both in terms of survival and quality of life. Since opening in November 2020, BRAIN MATRIX has recruited over 190 patients across 8 NHS hospitals, and is planning to expand to further centres in the coming year.

More information on the study can be found on the BRAIN MATRIX website.